Related Experiment Video
Updated: Apr 25, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Use of a claims database to characterize and estimate the incidence rate for Castleman disease
Nikhil Munshi1, Maneesha Mehra, Helgi van de Velde
1Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA.
Abstract:
Castleman disease (CD) is a rare lymphoproliferative disorder affecting single (unicentric; UCD) or multiple (multicentric; MCD) lymph nodes. The incidence of this difficult to diagnose disease is poorly understood, as no International Classification of Diseases, Ninth Revision (ICD-9) code is available. This study utilized a unique strategy to estimate its incidence using two commercial claims databases, IMS LifeLink™ and Truven Health Analytics MarketScan(®). Patients with an index diagnosis of lymphadenopathy (ICD-9 code 785.6) were followed longitudinally for 1 year prior to and 2 years post-index diagnosis date. An algorithm that identifies potential patients with CD was developed to determine the incidence rate in person-years. The incidence rate for CD was calculated as 21 (IMS LifeLink™) and 25 (MarketScan(®)) per million person-years. Additionally, 23% of patients with CD were identified as potentially suffering from MCD. These results are consistent with the definition of an orphan disease, and the low incidence of the disease estimated in the literature.
More Related Videos
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Kaplan-Meier Approach
Cancer Survival Analysis
Hazard Ratio
For example, in a clinical trial...
Comparing the Survival Analysis of Two or More Groups
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...